Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies. Discussion These therapies are based ...

View the live stream, or join us through our Webex meeting link, starting at 7:50 a.m. Wednesday Oregon Health & Science University is dedicated to improving the health and quality of life for all ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average recommendation of “Buy” by the nine brokerages that are covering the stock, MarketBeat.com reports.

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

The anti-amyloid therapy branded as Leqembi is currently indicated in the U.S. as an intravenous therapy for early Alzheimer’s disease. The subcutaneous autoinjector, named lecanemab-irmb ...